Assignee
ONTARIO INSTITUTE FOR CANCER RES OICR
CA·12 granted patents·13 pending applications·7 citations·filing 2015–2025
Top patents by PatentIndex Score
25 records- 0186US11505539B2Deuterated compounds as inhibitors of the BCL6 BTB domain protein-protein interaction and/or as BCL6 degradersONTARIO INSTITUTE FOR CANCER RES OICR·Filed 2018·Granted Nov 22, 2022·3 cites·16 claims
- 0280US11518764B2Substituted heteroaryls as inhibitors of the BCL6 BTB domain protein-protein interactionONTARIO INSTITUTE FOR CANCER RES OICR·Filed 2019·Granted Dec 6, 2022·3 cites·18 claims
- 0379US11576981B2Acyl hydrazone linkers, methods and uses thereofONTARIO INSTITUTE FOR CANCER RES OICR·Filed 2018·Granted Feb 14, 2023·1 cites·20 claims
- 0463US2024018600A1Mitochondrial dna prostate cancer marker and related systems and methodsONTARIO INSTITUTE FOR CANCER RES OICR·Filed 2022·Application pending·0 cites
- 0562US2025313902A1Cancer risk based on tumour clonalityONTARIO INSTITUTE FOR CANCER RES OICR·Filed 2025·Application pending·0 cites
- 0656US2024343704A1Halo-substituted amino pyridine compounds as inhibitors of the haematopoietic progenitor kinase 1 (hpk1)ONTARIO INSTITUTE FOR CANCER RES OICR·Filed 2022·Application pending·0 cites
- 0755US11192880B2Quinolone compounds as inhibitors of the BCL6 BTB domain protein-protein interaction and/or as BCL6 degradersONTARIO INSTITUTE FOR CANCER RES OICR·Filed 2018·Granted Dec 7, 2021·0 cites·11 claims
- 0855US2024425479A1Halo-substituted amino aza-heteroaryl compounds as inhibitors of the haematopoietic progenitor kinase 1 (hpk1)ONTARIO INSTITUTE FOR CANCER RES OICR·Filed 2022·Application pending·0 cites
- 0955US2023330244A1Nicotinamide phosphoribosyltransferase (nampt) inhibitor-conjugates and uses thereofONTARIO INSTITUTE FOR CANCER RES OICR·Filed 2021·Application pending·0 cites
- 1054US2024317723A1Substituted amino aza-heteroaryl compounds as inhibitors of the haematopoietic progenitor kinase 1 (hpk1)ONTARIO INSTITUTE FOR CANCER RES OICR·Filed 2022·Application pending·0 cites
- 1153US12286678B2Cancer risk based on tumour clonalityONTARIO INSTITUTE FOR CANCER RES OICR·Filed 2018·Granted Apr 29, 2025·0 cites·13 claims
- 1253US2024092763A1Isoindolinone aminopyrimidine compounds as inhibitors of nuak kinases, compositions and uses thereofONTARIO INSTITUTE FOR CANCER RES OICR·Filed 2022·Application pending·0 cites
- 1353US2025043355A1Pan-cancer transcriptional signatureONTARIO INSTITUTE FOR CANCER RES OICR·Filed 2020·Application pending·0 cites
- 1453US2024025887A1Thienyl and cycloalkyl aminopyrimidine compounds as inhibitors of nuak kinases, compositions and uses thereofONTARIO INSTITUTE FOR CANCER RES OICR·Filed 2022·Application pending·0 cites
- 1551US11499195B2Mitochondrial DNA prostate cancer marker and related systems and methodsONTARIO INSTITUTE FOR CANCER RES OICR·Filed 2017·Granted Nov 15, 2022·0 cites·13 claims
- 1650US2022313832A1Nicotinamide phosphoribosyltransferase (nampt) inhibitor-conjugates and uses thereofONTARIO INSTITUTE FOR CANCER RES OICR·Filed 2020·Application pending·0 cites
- 1750US2023105654A1Molecular classifiers for prostate cancerONTARIO INSTITUTE FOR CANCER RES OICR·Filed 2021·Application pending·0 cites
- 1849US11850287B2Heterocyclic acyl hydrazone linkers, methods and uses thereofONTARIO INSTITUTE FOR CANCER RES OICR·Filed 2018·Granted Dec 26, 2023·0 cites·19 claims
- 1949US2022267281A1Unsaturated heterocycloalkyl and heteroaromatic acyl hydrazone linkers, methods and uses thereofONTARIO INSTITUTE FOR CANCER RES OICR·Filed 2020·Application pending·0 cites
- 2042US11242351B2Tricyclic inhibitors of the BCL6 BTB domain protein-protein interaction and uses thereofONTARIO INSTITUTE FOR CANCER RES OICR·Filed 2018·Granted Feb 8, 2022·0 cites·14 claims
- 2140US12186401B2Amide-based proteolysis modulators of B-rapidly accelerated fibrosarcoma (BRAF) and associated usesONTARIO INSTITUTE FOR CANCER RES OICR·Filed 2020·Granted Jan 7, 2025·0 cites·20 claims
- 2240US11015226B2Targeting the histone pathway to detect and overcome anthracyclin resistanceONTARIO INSTITUTE FOR CANCER RES OICR·Filed 2016·Granted May 25, 2021·0 cites·9 claims
- 2338US2019055608A1Multi-modal prostate cancer markerONTARIO INSTITUTE FOR CANCER RES OICR·Filed 2017·Application pending·0 cites
- 2428US11566292B2Gene signature of residual risk following endocrine treatment in early breast cancerONTARIO INSTITUTE FOR CANCER RES OICR·Filed 2016·Granted Jan 31, 2023·0 cites·9 claims
- 2528US10745760B2Biopsy-driven genomic signature for prostate cancer prognosisONTARIO INSTITUTE FOR CANCER RES (OICR)·Filed 2015·Granted Aug 18, 2020·0 cites·13 claims
Join the waitlist — get patent alerts
Get an alert when ONTARIO INSTITUTE FOR CANCER RES OICR files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →